Lifestyle
- Regular weight-bearing exercise
- Adequate sun exposure for vitamin D
- Smoking cessation
Bone Gla Protein · BGP · Osteocalcin
Osteocalcin quantifies the level of a bone-derived hormone involved in bone formation and metabolism.
Ranges may vary with age and sex; fasting and time of day can affect results.
Osteocalcin, also known as Bone Gla Protein (BGP), is a non-collagenous protein hormone found in bone and dentin, secreted by osteoblasts. It is a vitamin K-dependent protein that plays a crucial role in the regulation of bone mineralization and calcium ion homeostasis. Researchers have identified osteocalcin as a marker for bone formation, with its levels reflecting the activity of osteoblasts. Clinically, osteocalcin is significant in assessing bone metabolism disorders such as osteoporosis. Elevated osteocalcin levels are often associated with increased bone turnover, which can be indicative of bone loss conditions. Conversely, low levels may suggest reduced bone formation or a deficiency in vitamin K. In the context of athletic performance and biohacking, osteocalcin is of interest due to its role in energy metabolism and potential influence on muscle function. It has been observed to interact with insulin secretion and sensitivity, suggesting a broader impact on metabolic health. However, the interpretation of osteocalcin levels can be confounded by factors such as age, sex, and vitamin K status. Additionally, time-of-day variations and fasting states can affect osteocalcin measurements, necessitating standardized testing conditions for accurate assessment.
Klinische Bedeutung
Elevated osteocalcin levels may indicate high bone turnover, often seen in osteoporosis or hyperparathyroidism. Reduced levels can suggest low bone formation or vitamin K deficiency.
Progressively rising osteocalcin levels may suggest increased bone turnover, warranting further investigation for osteoporosis or other metabolic bone diseases. Retest in 3-6 months.
Progressively falling levels could indicate reduced bone formation or improved bone health in response to treatment.
Re-test Interval
6 months if outside optimal range
Note:
Consult a healthcare provider before starting any supplementation, especially if on anticoagulant therapy.
Levels may vary throughout the day; morning samples are preferred.
Testing Frequency
Annually for those at risk of bone density loss, more frequently if undergoing treatment for osteoporosis.
May affect
Current research suggests that the role of osteocalcin in cardiovascular risk remains unclear, particularly regarding reference ranges and the optimal ucOC/cOC ratio as an indicator of vitamin K status. Researchers have not yet established the precise mechanisms linking osteocalcin to adolescent psychopathology, leaving questions about its potential as a transdiagnostic biomarker. Additionally, the impact of dietary factors on osteocalcin levels and their clinical implications in various populations remains an area for further exploration.
Research publications about Osteocalcin over time
8totalLog lab results, track trends and optimize your biomarkers over time.
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer